{"id":13669,"date":"2024-07-18T12:07:00","date_gmt":"2024-07-18T12:07:00","guid":{"rendered":"https:\/\/www.gruenhorn.group\/?p=13669"},"modified":"2024-08-01T12:48:51","modified_gmt":"2024-08-01T12:48:51","slug":"gruenhorn-ceo-ueber-g-ba-entscheid-zu-cannabis-auf-kassenleistung","status":"publish","type":"post","link":"https:\/\/www.gruenhorn.group\/en\/gruenhorn-ceo-ueber-g-ba-entscheid-zu-cannabis-auf-kassenleistung\/","title":{"rendered":"Gr\u00fcnhorn CEO on G-BA decision on cannabis as a statutory health insurance benefit"},"content":{"rendered":"<h2 class=\"wp-block-heading\"> \"Less Waiting Time for Patients \u2013 More Trust in Doctors\"<\/h2>\n\n\n\n<p><strong>The Federal Joint Committee (G-BA) today approved changes to the initial prescription of medicinal cannabis. They are intended to make access to cannabis medicines considerably easier.<\/strong><\/p>\n\n\n\n<p>Currently, it takes an average of three weeks for a health insurance company to decide on a cannabis therapy request. This is because an initial prescription usually required approval. The waiting often involves significant suffering for patients, who include those with cancer, multiple sclerosis, or chronic pain. Previously, 30 to 40 percent of applications were rejected by various health insurance companies. This led to fewer prescribers being willing to submit applications. The new regulations aim to change this by allowing specialists with additional qualifications to make their own decisions about cannabis prescriptions without needing approval:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The G-BA's decision on July 18, 2024, introduces exceptions to the approval requirement.<\/li>\n\n\n\n<li>The application from the Kassen\u00e4rztliche Bundesvereinigung (KBV) with patient representatives and the G-BA was accepted (seven votes to six against the votes of the GKV-Spitzenverband).<\/li>\n\n\n\n<li>The regulation was initiated under the Supply Shortage Act (ALBVVG, July 2023) and aims to make THC medications more easily available to those who need them, especially for severe conditions.<\/li>\n\n\n\n<li>Doctors with the appropriate qualifications can prescribe medicinal cannabis without prior approval from health insurance companies.<\/li>\n\n\n\n<li>According to the application, this applies to specialists in neurology, psychiatry, oncology, infectious diseases, gynecology, geriatrics, gastroenterology, and general practitioners participating in general outpatient palliative care (AAPV).<\/li>\n\n\n\n<li>Required additional training ensures that doctors can assess cannabis therapy effectively and includes specializations such as pain therapy, palliative medicine, sleep medicine, social medicine, basic addiction medicine, medication-based tumor therapy, and geriatrics.<\/li>\n\n\n\n<li>A review of the regulation will also take place after 15 months (based on the number of prescriptions by specialist groups and applications for cost coverage, regressions, and review procedures).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Gr\u00fcnhorn\u2019s CEO and Medical Experts Welcome the Decision<\/h3>\n\n\n\n<p><em>\u201cThe regulation is a crucial step towards easing access to medicinal cannabis for those who need it,<\/em>\u201d says Stefan Fritsch, CEO of the Gr\u00fcnhorn Group. Gr\u00fcnhorn has been dedicated to improving the supply of medicinal cannabis for years and views the regulation as part of a positive shift. <em>\u201cWe have firsthand experience of how difficult it often was to receive necessary treatments. It is therefore even more important that, following the partial legalization of cannabis in Germany, the regulations for prescribing THC-containing medical products are now being simplified. This means less waiting time for patients \u2013 and more trust in doctors,<\/em>\u201d adds Fritsch.<\/p>\n\n\n\n<p>In some cases, severe fates are linked with the bureaucracy in the reimbursement process for medicinal cannabis. As an example, Dr. Lorenz Eberle, a physician, cites a case from his practice: <em>\u201cMany patients cannot afford to pay for their treatment themselves. I think of one of my epilepsy patients, for whom cannabis therapy could have been very successful but was denied. For such people, it is a significant advancement if treating doctors are trusted more and can make decisions easily.\"<\/em><br>Dr. Eberle continues:<em>\u201cIf a doctor prescribes a cannabis medication, the insurance should cover it as well. For a diabetes medication, no one questions it every time. The planned additional qualifications are a step in the right direction to ensure that specialists are well-informed about cannabis.<\/em> \u201d When dealing with serious illnesses, waiting adds an additional burden. The G-BA decision leads to faster processes and can thus have a significant positive impact on the quality of life for many people with similar experiences.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Sources:<\/h3>\n\n\n\n<p><sup>https:\/\/www.g-ba.de\/presse\/pressemitteilungen-meldungen\/1098\/<br>https:\/\/www.g-ba.de\/downloads\/17-98-5451\/2023-03-16_FAQ%20Cannabisarzneimittel.pdf<br>KBV &#8211; Kassen\u00e4rztliche Bundesvereinigung<br>https:\/\/www.deutsche-apotheker-zeitung.de\/news\/artikel\/2018\/04\/16\/das-koennte-die-krankenkasse-ueberzeugen<\/sup><\/p>","protected":false},"excerpt":{"rendered":"<p>\u201eWeniger Wartezeit f\u00fcr Patienten \u2013 mehr Vertrauen in \u00c4rzte\u201c Der Gemeinsame Bundesausschuss (G-BA) hat heute \u00c4nderungen f\u00fcr die Erstverordnung von medizinischem Cannabis beschlossen. Sie sollen den Zugang zu Cannabis-Arzneimitteln erheblich erleichtern. Drei Wochen \u2013 so lange dauert es bisher im Schnitt, bis eine Krankenkasse f\u00fcr oder gegen eine Cannabistherapie entscheidet. Denn: Bei der Erstverordnung bedurfte [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":13672,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-13669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressemeldungen"],"uagb_featured_image_src":{"full":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten.webp",1200,600,false],"thumbnail":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten-150x150.webp",150,150,true],"medium":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten-300x150.webp",300,150,true],"medium_large":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten-768x384.webp",768,384,true],"large":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten-1024x512.webp",1024,512,true],"1536x1536":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten.webp",1200,600,false],"2048x2048":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten.webp",1200,600,false],"trp-custom-language-flag":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/07\/G-Ba-Bescheid-zu-Cannabis-auf-Kassenkosten.webp",18,9,false]},"uagb_author_info":{"display_name":"rsuessenbach","author_link":"https:\/\/www.gruenhorn.group\/en\/author\/rsuessenbach\/"},"uagb_comment_info":0,"uagb_excerpt":"\u201eWeniger Wartezeit f\u00fcr Patienten \u2013 mehr Vertrauen in \u00c4rzte\u201c Der Gemeinsame Bundesausschuss (G-BA) hat heute \u00c4nderungen f\u00fcr die Erstverordnung von medizinischem Cannabis beschlossen. Sie sollen den Zugang zu Cannabis-Arzneimitteln erheblich erleichtern. Drei Wochen \u2013 so lange dauert es bisher im Schnitt, bis eine Krankenkasse f\u00fcr oder gegen eine Cannabistherapie entscheidet. Denn: Bei der Erstverordnung bedurfte&hellip;","_links":{"self":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13669"}],"collection":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/comments?post=13669"}],"version-history":[{"count":2,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13669\/revisions"}],"predecessor-version":[{"id":13911,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13669\/revisions\/13911"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/media\/13672"}],"wp:attachment":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/media?parent=13669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/categories?post=13669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/tags?post=13669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}